

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Resources Medical Holdings Company Limited

華潤醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1515)

POSITIVE PROFIT ALERT

This announcement is made by China Resources Medical Holdings Company Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) of Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcement of the Company dated June 30, 2023 (the “**Announcement**”) and the circular of the Company dated April 27, 2023 (the “**Circular**”) all in relation to the major and connected transaction in relation to the acquisitions of the LH Subject Equity, JE Subject Equity and JE Subject Debts. Unless otherwise stated, capitalised terms used herein shall have the same meanings as those defined in the Circular.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that the Company is in the course of preparing its consolidated financial results for the six months ended June 30, 2023 (the “**Reporting Period**”). Based on the information currently available to the Company and the preliminary review on the Group’s unaudited consolidated management accounts for the Reporting Period, the Group expects that the profit for the period attributable to owners of the parent company of the Group as contained in the consolidated financial statements for the Reporting Period would increase by approximately 60% as compared with the restated figures (as described below) for the corresponding period in year 2022. The increase was mainly attributable to the consolidation arrangement regarding the LH Subjects and the JE Subject where the Group will retrospectively consolidate the financial results of the LH Subjects and the JE

Subject from June 2, 2022. As such, the financial results of the LH Subjects and the JE Subject for the six months ended June 30, 2023 will be consolidated into those of the Group for the same period, while only the financial results of the LH Subjects and the JE Subject for the period from June 2, 2022 to June 30, 2022 will be consolidated into those of the Group as comparative figures for the corresponding period in year 2022. Please refer to the Announcement for further details of the aforesaid consolidation arrangement of the Group regarding the LH Subjects and the JE Subject.

The Company is still in the process of finalising the Group's consolidated financial results for the Reporting Period. The information contained in this announcement is only based on the information currently available to the Company and the preliminary assessment with reference to the unaudited management accounts of the Group for the Reporting Period, which are yet to be reviewed by the auditors of the Company.

Shareholders and potential investors should exercise caution when dealing in the shares of the Company and are advised to refer to the details in the interim results announcement to be published by the Company for the Reporting Period.

By order of the Board
China Resources Medical Holdings Company Limited
SONG Qing
Chairman

Shenzhen, August 9, 2023

As at the date of this announcement, the Board comprises Mr. SONG Qing, Mr. YU Hai, Mr. SHAN Baojie and Ms. YANG Min as executive Directors; Mr. HU Hui as non-executive Director; Mr. WU Ting Yuk, Anthony, Mr. KWONG Kwok Kong and Mr. FU Tingmei as independent non-executive Directors.